Status:

TERMINATED

Patients With Heart Failure ANd Type 2 Diabetes Treated With Placebo Or Metformin (PHANTOM) Pilot Study

Lead Sponsor:

University of Alberta

Conditions:

Diabetes Mellitus, Type 2

Heart Failure, Congestive

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

To conduct a pilot study to evaluate the feasibility of a large randomized controlled trial (RCT) of metformin in patients with heart failure and type 2 diabetes and to generate initial morbidity and ...

Detailed Description

Background: Heart failure (HF) is a common complication of type 2 diabetes mellitus. There are limited treatment options for patients with HF and diabetes. Although metformin is considered a safe and ...

Eligibility Criteria

Inclusion

  • All subjects with physician-diagnosed symptomatic heart failure (NYHA class I, II, III, IV) and type 2 diabetes.
  • A diagnosis of type 2 diabetes defined as:
  • a previous physician diagnosis of type 2 diabetes as documented in the subject's clinical record or;
  • receiving oral antihyperglycemic agents or;
  • a new diagnosis of type 2 diabetes during the visit within the heart failure clinic or hospital based on a fasting blood glucose ≥7.0 mmol/L or random blood glucose ≥11.1 mmol/L accompanied by acute metabolic decompensation or 2 hour plasma glucose in a 75 gram oral glucose tolerance test ≥11.1 mmol/L.

Exclusion

  • subjects currently receiving greater than 1500 mg of metformin therapy per day
  • subjects who are unwilling to change their antidiabetic regimens;
  • subjects receiving insulin therapy;
  • serum creatinine ≥ 180 μmol/L;
  • A1c \< 7.0 percent;
  • inability to communicate (language barrier);
  • dementia/mental illness;
  • age \< 18 years;
  • subjects unwilling to complete self-monitoring of serum blood sugars during the trial period.
  • those participating in another heart failure or diabetes clinical trial involving medication;
  • severe comorbidities or foreshortened life expectancy;
  • subjects who do not provide written informed consent to participate.

Key Trial Info

Start Date :

May 1 2006

Trial Type :

INTERVENTIONAL

End Date :

May 1 2007

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00325910

Start Date

May 1 2006

End Date

May 1 2007

Last Update

May 14 2008

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Misericordia Hospital

Edmonton, Alberta, Canada, T5R 4H5

2

University of Alberta Hospital

Edmonton, Alberta, Canada, T6G 2B7